Browse drugs

…ow (see section on Current treatments). The antifibrotic drugs, pirfenidone and nintedanib, are established treatments for idiopathic pulmo…

…–5 years from symptom onset. Antifibrotic agents–nintedanib and pirfenidone–slow disease progression and may extend survival. However, real…

…ine and follow-up in patients with ECV≥27% randomised (n=94) to pirfenidone or placebo, and at baseline only in patients who were not rando…

…tion and delayed dose reduction, suggesting improved adherence. Pirfenidone was associated with a higher rate of treatment discontinuation.…

…Background Pirfenidone and Nintedanib are antifibrotic medications licensed in the UK for Idopathetic…

…rotic eligibility, particularly reducing the proportion meeting pirfenidone thresholds. In contrast, GLI-2022 has minimal impact on modelle…

…ses (ILDs) other than idiopathic pulmonary fibrosis (IPF). Oral pirfenidone has been studied in non-IPF ILDs, but in smaller academic studi…

…t treatment for pulmonary fibrosis is limited to nintedanib and pirfenidone, which slow but do not halt or reverse the progression of the d…

…Introduction Nintedanib and pirfenidone reduce the rate of progression in fibrotic lung…

…33%. Longest use (days) was at 3192 for Nintedanib and 3127 for Pirfenidone. Since inception, RN/RPh-led monitoring has increased from 769 …

… criteria, 3,555 initiating nintendanib and/or 2,496 initiating pirfenidone. For all patients, mean (SD) age at initiation was 75.6(7.3), w…

… (IPF). In the phase 2a study INTEGRIS-IPF study (NCT04396756), bexotegrast was well tolerated and showed antifibrotic activity.Methods and…